 Silence Therapeutics PLC AIM:SLN, NASDAQ:SLN, OTC:SLNCF said healthcare-focused investment firm Frazier Life Sciences Public Fund purchased US20mln existing ordinary shares and is now a 3 shareholder in the company. The company, which is developing medicines harnessing the bodys natural mechanism of ribonucleic acid RNA interference, said Frazier Life Sciences has a track record of partnering with science-driven healthcare businesses. 